Non-Segmental Vitiligo (NSV), Vitiligo
Conditions
Keywords
Non-segmental Vitiligo, D-2570, Phase 2 Clinical Trial
Brief summary
This study tests D-2570, an investigational drug, in people with non-segmental vitiligo to check its safety and effect on skin discoloration. Eligible participants will take D-2570, or a placebo, once daily for 24 weeks in a double-blind setting. Most will then continue into a 24-week extension phase All participants will have a 4-week safety follow-up after treatment ends, with regular check-ups and blood tests throughout the study.
Detailed description
This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled, parallel-group study designed to evaluate the safety and efficacy of D-2570 in subjects with non-segmental vitiligo. The study consists of three periods: a screening period (up to 4 weeks), a 24-week double-blind treatment period, and a 24-week extension treatment period, followed by a 4-week safety follow-up period. During the screening period, written informed consent will be obtained from each subject, and eligibility will be assessed based on predefined inclusion and exclusion criteria. Subjects who meet all eligibility criteria will be stratified according to baseline vitiligo severity (T-VASI \<15 or ≥15) and disease activity (active or stable), then randomized in a 1:1:1:1 ratio to one of four treatment groups: D-2570 Group A, D-2570 Group B, D-2570 Group C, or placebo. During the 24-week double-blind treatment period, subjects will receive once-daily oral study medication. Subjects in Groups A and B will continue the same dose in the subsequent 24-week extension period. Subjects in Group C and the placebo group will be re-randomized in a 1:1 ratio to either Group A or Group B for the extension period, maintaining the blind. All subjects will attend study visits at protocol-specified time points, including assessments of efficacy (including T-VASI), safety (including adverse events, clinical laboratory tests, vital signs, and physical examinations), and pharmacokinetic evaluations via blood sampling. The study will conclude with an end-of-study (EOS) visit at Week 52, 4 weeks after the last dose of study medication, to collect final safety data. All subjects, investigators, and study site personnel will remain blinded to treatment assignments throughout the study.
Interventions
DRUGD-2570 Dose 1
Oral D-2570 Dose 1 administered once daily for 24 weeks during the double-blind treatment period. Eligible subjects may continue the same dose in the 24-week extension period
DRUGD-2570 Dose 2
Oral D-2570 Dose 2 administered once daily for 24 weeks during the double-blind treatment period. Eligible subjects may continue the same dose in the 24-week extension period.
DRUGPlacebo
Oral placebo administered once daily for 24 weeks during the double-blind treatment period. Subjects will be re-randomized to D-2570 Dose 1 or Dose 2 in the extension period.
DRUGD-2570 Dose 3
Oral D-2570 Dose 3 administered once daily for 24 weeks during the double-blind treatment period. Subjects will be re-randomized to D-2570 Dose 1 or Dose 2 in the extension period.
Sponsors
InventisBio Co., Ltd
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Masking description
All participants, care providers, investigators, and outcomes assessors are blinded to treatment assignment throughout the study
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Voluntarily signs informed consent and complies with study procedures. * Age 18-65 years, male or female. * Clinical diagnosis of non-segmental vitiligo at screening. * F-VASI ≥0.25 and T-VASI ≥5 at screening and baseline, with either active or stable vitiligo. * Women of childbearing potential have negative pregnancy tests at screening and baseline. All eligible subjects agree to effective contraception from consent through 30 days after last study drug dose.
Exclusion criteria
* \- Segmental, mixed vitiligo or other concurrent pigmentary/active skin disorders interfering with study assessment. * Over 33% facial or total vitiligo lesions with leukotrichia. * Pregnant or breastfeeding females. * Active, latent or inadequately treated tuberculosis infection. * Positive HIV, active HBV/HCV infection, or untreated syphilis. * Current or history of severe herpes infection. * Severe systemic infection requiring recent inpatient, intravenous or oral anti-infective treatment. * Congenital or acquired immune deficiency, opportunistic infection history, or conditions requiring systemic immunosuppression during the study. * Uncontrolled thyroid disease, severe cardiovascular/cerebrovascular disease or other unstable severe systemic disorders. * Severe psychiatric disease, suicidal ideation, or alcohol/drug abuse within 6 months. * Malignancy history within 5 years (excluding cured non-melanoma skin cancer and cervical intraepithelial neoplasia). * Gastrointestinal disease affecting drug absorption or major surgery within 8 weeks prior to dosing. * Clinically significant abnormal lab results: elevated liver/renal indices, decreased hemoglobin, WBC, platelet, lymphocyte or neutrophil counts. * History of severe drug hypersensitivity or drug-related toxicity. * Any condition that may impair protocol compliance or study participation per investigator judgment.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Percentage change from baseline in Facial Vitiligo Area Scoring Index (F-VASI) | week24 | Change rate of facial vitiligo area, measured by F-VASI score, relative to baseline |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change and percentage change from baseline in F-VASI | Weeks 4, 8, 12, 16, 20, 24, 32, 40, and 48 | Absolute change and percentage change in facial vitiligo area, measured by F-VASI score, relative to baseline. |
| Proportion of subjects achieving F-VASI50/75/90 | Weeks 4, 8, 12, 16, 20, 24, 32, 40, and 48 | Percentage of subjects with ≥50%, ≥75%, or ≥90% reduction in F-VASI score from baseline. |
| Change and percentage change from baseline in T-VASI | Weeks 4, 8, 12, 16, 20, 24, 32, 40, and 48 | Absolute change and percentage change in total vitiligo area, measured by T-VASI score, relative to baseline. |
| Proportion of subjects achieving T-VASI50/75/90 | Weeks 4, 8, 12, 16, 20, 24, 32, 40, and 48 | Percentage of subjects with ≥50%, ≥75%, or ≥90% reduction in T-VASI score from baseline. |
| Proportion of subjects with F-PhGVA score 0 or 1 | Weeks 8, 16, 24, 32, 40, and 48 | Percentage of subjects with F-PhGVA score of 0 (clear) or 1 (almost clear). |
| Proportion of subjects with T-PhGVA score 0 or 1 | Weeks 8, 16, 24, 32, 40, and 48 | Percentage of subjects with T-PhGVA score of 0 (clear) or 1 (almost clear). |
| Proportion of subjects with VNS score 4 or 5 | Weeks 8, 16, 24, 32, 40, and 48 | Percentage of subjects with VNS score of 4 (hardly noticeable) or 5 (not noticeable). |
| Change from baseline in DLQI score | Weeks 8, 16, 24, 32, 40, and 48 | Change in Dermatology Quality of Life Index (DLQI) score relative to baseline. |
| Change from baseline in VitiQoL score | Weeks 8, 16, 24, 32, 40, and 48 | Change in Vitiligo-Specific Quality of Life (VitiQoL) score relative to baseline. |
| Plasma concentrations of D-2570 | Through study completion (approximately Week 48) | — |
| Safety of D-2570（AEs） | Through study completion (approximately Week 48) | — |
Countries
China
Contacts
CONTACTshilin Sha
Outcome results
None listed